Hypoxia-ameliorated photothermal manganese dioxide nanoplatform for reversing doxorubicin resistance

Drug resistance is a huge hurdle in tumor therapy. Tumor hypoxia contributes to chemotherapy resistance by inducing the hypoxia-inducible factor-1α (HIF-1α) pathway. To reduce tumor hypoxia, novel approaches have been devised, providing significant importance to reverse therapeutic resistance and im...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 14; p. 1133011
Main Authors Chen, Zhenzhen, Liu, Zhihong, Zhang, Qian, Huang, Sheng, Zhang, Zaizhong, Feng, Xianquan, Zeng, Lingjun, Lin, Ding, Wang, Lie, Song, Hongtao
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 24.02.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Drug resistance is a huge hurdle in tumor therapy. Tumor hypoxia contributes to chemotherapy resistance by inducing the hypoxia-inducible factor-1α (HIF-1α) pathway. To reduce tumor hypoxia, novel approaches have been devised, providing significant importance to reverse therapeutic resistance and improve the effectiveness of antitumor therapies. Herein, the nanosystem of bovine serum albumin (BSA)-templated manganese dioxide (MnO ) nanoparticles (BSA/MnO NPs) loaded with doxorubicin (DOX) (DOX-BSA/MnO NPs) developed in our previous report was further explored for their physicochemical properties and capacity to reverse DOX resistance because of their excellent photothermal and tumor microenvironment (TME) response effects. The DOX-BSA/MnO NPs showed good biocompatibility and hemocompatibility. Meanwhile, DOX-BSA/MnO NPs could greatly affect DOX pharmacokinetic properties, with prolonged circulation time and reduced cardiotoxicity, besides enhancing accumulation at tumor sites. DOX-BSA/MnO NPs can interact with H O and H in TME to form oxygen and exhibit excellent photothermal effect to further alleviate hypoxia due to MnO , reversing DOX resistance by down-regulating HIF-1α expression and significantly improving the antitumor efficiency in DOX-resistant human breast carcinoma cell line (MCF-7/ADR) tumor model. The hypoxia-ameliorated photothermal MnO platform is a promising strategy for revering DOX resistance.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Yuning Zhang,First Hospital of Jilin University, China
These authors have contributed equally to this work
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology
Leli Zeng, Sun Yat-sen University, China
Reviewed by: Yuan Tang, University of Toledo, United States
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2023.1133011